Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast Cancer

Next Previous
X
Search
Trial Profile

Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adebrelimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Dalpiciclib (Primary) ; Exemestane (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUKDEN 03

    • Most Recent Events

    • 02 Jan 2024 Planned End Date changed from 15 Oct 2023 to 31 Dec 2028.
    • 02 Jan 2024 Planned primary completion date changed from 15 Jul 2023 to 31 Dec 2024.
    • 06 Jun 2023 Primary endpoint (Residual cancer burden (RCB) 0-I index for HER2-/HR+BC group) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top